Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Capecitabine and Lapatinib in SCCHN
NCT01044433Phase 2Completed
- Sponsor
- Abramson Cancer Center
- Start
- Oct 2009
- Primary completion
- Sep 2015
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of lapatinib, capecitabine in squamous cell carcinoma of the head and neck (HNSCC), sponsored by Abramson Cancer Center. Started Oct 2009; status: completed.
02
Drugs
lapatinibcapecitabine
03
Conditions
squamous cell carcinoma of the head and neck (HNSCC)
Beyond the preview
Go deeper on NCT01044433.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01044433.